AR054514A1 - Derivados de pirazolopiridina como inhibidores del receptor beta-adrenergico cinasa 1 - Google Patents

Derivados de pirazolopiridina como inhibidores del receptor beta-adrenergico cinasa 1

Info

Publication number
AR054514A1
AR054514A1 ARP060102721A ARP060102721A AR054514A1 AR 054514 A1 AR054514 A1 AR 054514A1 AR P060102721 A ARP060102721 A AR P060102721A AR P060102721 A ARP060102721 A AR P060102721A AR 054514 A1 AR054514 A1 AR 054514A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
substituted
heterocyclyl
halogen
Prior art date
Application number
ARP060102721A
Other languages
English (en)
Spanish (es)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR054514A1 publication Critical patent/AR054514A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP060102721A 2005-06-27 2006-06-23 Derivados de pirazolopiridina como inhibidores del receptor beta-adrenergico cinasa 1 AR054514A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05013774 2005-06-27

Publications (1)

Publication Number Publication Date
AR054514A1 true AR054514A1 (es) 2007-06-27

Family

ID=35395578

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102721A AR054514A1 (es) 2005-06-27 2006-06-23 Derivados de pirazolopiridina como inhibidores del receptor beta-adrenergico cinasa 1

Country Status (30)

Country Link
US (1) US7910602B2 (https=)
EP (1) EP1899333B1 (https=)
JP (1) JP5010594B2 (https=)
KR (1) KR20080020638A (https=)
CN (1) CN101208340B (https=)
AR (1) AR054514A1 (https=)
AT (1) ATE423118T1 (https=)
AU (1) AU2006264044A1 (https=)
BR (1) BRPI0612320A2 (https=)
CA (1) CA2611296A1 (https=)
CY (1) CY1110464T1 (https=)
DE (1) DE602006005242D1 (https=)
DK (1) DK1899333T3 (https=)
ES (1) ES2322197T3 (https=)
HR (1) HRP20090244T2 (https=)
IL (1) IL188381A0 (https=)
MA (1) MA29498B1 (https=)
MX (1) MX2007015829A (https=)
MY (1) MY139016A (https=)
NO (1) NO20080392L (https=)
NZ (1) NZ564757A (https=)
PL (1) PL1899333T3 (https=)
PT (1) PT1899333E (https=)
RS (1) RS50821B (https=)
RU (1) RU2415855C2 (https=)
SI (1) SI1899333T1 (https=)
TW (1) TW200800982A (https=)
UY (1) UY29632A1 (https=)
WO (1) WO2007000241A1 (https=)
ZA (1) ZA200709853B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815438A (en) 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
GB201410815D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
CN112955450A (zh) * 2018-10-24 2021-06-11 百时美施贵宝公司 经取代的吲哚和吲唑化合物
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
EP4041730A1 (en) 2019-10-01 2022-08-17 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
WO2024137671A1 (en) * 2022-12-20 2024-06-27 Exelixis, Inc. Compounds that inhibit pkmyt1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034563A1 (en) * 1994-06-16 1995-12-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
ATE355841T1 (de) * 1997-12-13 2007-03-15 Bristol Myers Squibb Co Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
BR0313262A (pt) * 2002-08-07 2005-07-12 Mitsubishi Pharma Corp Compostos de dihidropirazolpiridina
KR101312736B1 (ko) * 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체

Also Published As

Publication number Publication date
NZ564757A (en) 2009-12-24
DE602006005242D1 (de) 2009-04-02
UY29632A1 (es) 2007-01-31
PT1899333E (pt) 2009-04-23
MX2007015829A (es) 2008-02-22
RU2008102970A (ru) 2009-08-10
MY139016A (en) 2009-08-28
ATE423118T1 (de) 2009-03-15
CA2611296A1 (en) 2007-01-04
ES2322197T3 (es) 2009-06-17
CN101208340A (zh) 2008-06-25
JP5010594B2 (ja) 2012-08-29
TW200800982A (en) 2008-01-01
WO2007000241A1 (en) 2007-01-04
KR20080020638A (ko) 2008-03-05
NO20080392L (no) 2008-02-28
RU2415855C2 (ru) 2011-04-10
US20080227777A1 (en) 2008-09-18
RS50821B (sr) 2010-08-31
MA29498B1 (fr) 2008-05-02
EP1899333B1 (en) 2009-02-18
CN101208340B (zh) 2010-12-22
IL188381A0 (en) 2008-04-13
US7910602B2 (en) 2011-03-22
HRP20090244T2 (hr) 2009-07-31
EP1899333A1 (en) 2008-03-19
SI1899333T1 (sl) 2009-08-31
CY1110464T1 (el) 2015-04-29
DK1899333T3 (da) 2009-06-15
ZA200709853B (en) 2008-12-31
JP2008543957A (ja) 2008-12-04
BRPI0612320A2 (pt) 2010-11-09
HRP20090244T1 (en) 2009-06-30
AU2006264044A1 (en) 2007-01-04
PL1899333T3 (pl) 2009-07-31

Similar Documents

Publication Publication Date Title
AR054514A1 (es) Derivados de pirazolopiridina como inhibidores del receptor beta-adrenergico cinasa 1
PE20070141A1 (es) Derivados de isoquinolina como inhibidores de rho-cinasa
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
RU2008145701A (ru) Производные пурина для применения в качестве агонистов аденозинового рецептора a2a
PE20090546A1 (es) Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20061332A1 (es) Derivados de piperidina como agentes inhibidores de la renina
AR068051A1 (es) Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer.
PE20110679A1 (es) Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
PE20050013A1 (es) Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c
PE20060297A1 (es) Nuevos derivados fluoroglicosidicos de pirazoles como inhibidores de sglt 1
AR039403A1 (es) Derivados de acil-4-carboxifenilurea y su uso como antidiabetico
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20091732A1 (es) Dihidropirazolonas sustituidas y su uso
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
AR056445A1 (es) Derivados arilicos y heteroarilicos de 6 miembros para tratar virus
PE20220252A1 (es) Compuestos de pirrol
DK1689742T3 (da) Quinoloncarboxylsyreforbindelser med 5-HT-receptor-agonistisk aktivitet
AR059032A1 (es) Combinacion de derivados de triazina y sensibilizadores de insulina
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5
PE20081657A1 (es) Derivados de ftalazina como antagonistas de los receptores de histamina h1
AR060904A1 (es) Derivados de 3,4-dihidro-2h-benzo [1,4] oxazina y tiazina como inhibidores de cetp
PE20071035A1 (es) DERIVADOS DE ESTER O ACIDO ACETICO COMO MODULADORES DEL RECEPTOR CRTh2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal